Loading market dashboard

Financials in USD. Standardized financial statements.
A compact view of how Acura Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.56M | $3.57M | $2.66M | $410,000 | $2.97M | $4.46M | $8.59M | $751,000 | $123,000 | $20.47M |
| Revenue Growth? | -56.2% | +34.4% | +548.0% | -86.2% | -33.6% | -48.0% | +1043.4% | +510.6% | -99.4% | 0.0% |
| Cost of Revenue? | $90,000 | $1.78M | $1,505 | $1,759 | $128,000 | $451,000 | $656,000 | $227,000 | $114,000 | $3,726 |
| Gross Profit? | $1.47M | $3.57M | $2.65M | $408,241 | $2.84M | $4.01M | $7.93M | $524,000 | $9,000 | -$3,726 |
| Gross Margin? | +94.2% | +99.9% | +99.9% | +99.6% | +95.7% | +89.9% | +92.4% | +69.8% | +7.3% | -0.0% |
| Operating Expenses? | $1.25M | $4.33M | $3.38M | $4.33M | $8.06M | $10.57M | $11.93M | $12.72M | $14.10M | $9.61M |
| Operating Income? | -$1.21M | -$758,000 | -$725,000 | -$3.92M | -$5.22M | -$6.56M | -$4.00M | -$12.20M | -$14.09M | -$9.74M |
| EBITDA? | -$589,000 | -$633,000 | -$3.04M | -$3.17M | -$4.93M | -$6.15M | -$3.56M | -$11.79M | -$13.76M | -$9.54M |
| Income Before Tax | -$879,000 | -$1.21M | -$3.77M | -$3.84M | -$5.82M | -$7.39M | -$4.99M | -$13.21M | -$13.90M | -$9.67M |
| Income Tax Expense | $0 | $0 | $0 | $0 | -$135,000 | $0 | $0 | $0 | $0 | -$71,000 |
| Net Income? | -$879,000 | -$1.21M | -$3.77M | -$3.84M | -$5.68M | -$7.39M | -$4.99M | -$13.21M | -$13.90M | -$9.67M |
| EPS? | $-0.02 | $-0.04 | $-0.14 | $-0.18 | $-0.36 | $-0.62 | $-0.46 | $-1.35 | $-1.46 | $-1.02 |
| Diluted EPS? | $-0.02 | $-0.04 | $-0.14 | $-0.18 | $-0.36 | $-0.62 | $-0.46 | $-1.35 | $-1.46 | $-1.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality